Aurobindo Pharma Secures US FDA Approval for Metered Beclomethasone Dipropionate Aerosol

Aurobindo Pharma Gains US FDA Approval for Beclomethasone Dipropionate Aerosol

The approval marks a significant milestone for Aurobindo Pharma as it expands its presence in the US respiratory market.

Understanding the Approval

The approved Abbreviated New Drug Application (ANDA) represents Aurobindo’s generic version of QVAR Inhalation Aerosol, which is marketed by Teva Branded Pharmaceutical Products R&D LLC. Beclomethasone Dipropionate is primarily indicated for the maintenance treatment of asthma in patients aged five years and older. This approval is particularly relevant for patients who may require systemic corticosteroids, as the aerosol can potentially reduce or eliminate the need for such treatments.

Market Potential and Strategic Importance

The US market for Beclomethasone Dipropionate and its newer versions, such as QVAR RediHaler, was valued at approximately $301 million for the twelve months ending July 2026, according to IQVIA. This approval not only enhances Aurobindo’s product portfolio but also positions the company to capture a share of this lucrative market segment. The product will be manufactured at Aurobindo’s facility in Raleigh, North Carolina, which is operated by its wholly owned subsidiary, Aurolife Pharma LLC.

Aurobindo’s Growing Portfolio

With this latest approval, Aurobindo Pharma’s cumulative ANDA approvals from the US FDA now total 596, which includes 571 final approvals and 25 tentative approvals. This robust pipeline of approvals underscores the company’s commitment to developing a diverse range of complex and differentiated products, enhancing its competitive edge in the pharmaceutical landscape.

Financial Performance and Market Reaction

In its recent financial results, Aurobindo reported a consolidated net profit increase of 25.20% to ₹1,032.56 crore, alongside a 16.86% rise in revenue to ₹9,105.82 crore for Q1 FY27 compared to the same quarter last year. Despite these positive financial indicators, the company’s stock experienced a slight decline of 1.15%, trading at ₹465 on the Bombay Stock Exchange (BSE). This drop could reflect broader market dynamics or investor sentiment rather than the fundamentals of the company.

Key Highlights

• Aurobindo Pharma receives US FDA approval for Beclomethasone Dipropionate HFA Inhalation Aerosol.
• The product is indicated for asthma maintenance treatment in patients aged five and older.
• The US market for the product is estimated at $301 million for the year ending July 2026.
• Aurobindo’s total US FDA ANDA approvals now stand at 596.
• The company reported a 25.20% increase in net profit for Q1 FY27.
• Despite strong financial performance, Aurobindo’s stock fell 1.15% to ₹465.

Investor Note: The recent FDA approval positions Aurobindo Pharma to capitalize on the growing asthma treatment market in the US. Investors should monitor the product launch timeline and market reception, as these factors will be crucial in determining the company’s future performance in this segment.